MedPath

The Efficacy of Hyperemesis Gravidarum on Macular Thickness, Corneal Thickness and Intraocular Pressure in Pregnancy

Not Applicable
Completed
Conditions
Corneal Dystrophy
Macular Dystrophy
Hyperemesis Gravidarum - Severe
Interventions
Diagnostic Test: Optic coherence tomography
Registration Number
NCT05927740
Lead Sponsor
Batman Training and Research Hospital
Brief Summary

Aim

Physiological changes in intraocular pressure as well as in the cornea and macula may occur during pregnancy.

In the literature, there are limited data on ocular findings in hyperemesis gravidarum. Therefore, we have decided to investigate the effect of hyperemesis gravidarum on macular thickness, corneal thickness and intraocular pressure (IOP).

Detailed Description

A total of 110 people, 55 of whom were diagnosed with hyperemesis gravidarum and 55 of whom were in the control group, were included in the study. The inclusion criteria for the study were as follows: First trimester (8-14 weeks of gestation) pregnancy with positive fetal heartbeat and no history of systemic disease; no continuous use of medication; diagnosis of hyperemesis gravidarum (ketonuria and weight \> 3 kg or 5% of the body) and the occurrence of less than three vomiting attacks per day with loss of weight; body mass index (BMI) within normal limits; being between the ages of 18 and 40; not drinking alcohol or smoking. A total of 94 patients, 40 of whom were diagnosed with hyperemesis gravidarum and 54 healthy pregnant women, were divided into two groups by recording their age, BMI, laboratory and eye findings.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
110
Inclusion Criteria
  • Inclusion criteria for the study;

    • First trimester (8-14 weeks of gestation) pregnancy with positive fetal heartbeat and no history of systemic disease ,
    • no history of continuous drug use,
    • Diagnosis of hyperemesis gravidarum (ketonuria and weight >3 kg or 5% of the body) The occurrence of >3 vomiting attacks per day with loss of weight,
    • Body mass index (BMI) within normal limits,
    • Being between the ages of 18-40 ,
    • not drinking alcohol or smoking,
    • not using any vitamins or supplements use during the study
Exclusion Criteria
  • Any patient who did not meet the inclusion criteria was excluded from the study.
  • Patients who participated in the study but later gave up

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2( Control group)Optic coherence tomography55 healthy pregnant women (11-14th gestational week of pregnancy)
1 ( Hyperemesis gravidarum )Optic coherence tomography55 hyperemesis gravidarum patient (11-14th gestational week of pregnancy)
Primary Outcome Measures
NameTimeMethod
Take precautions of the effect of hyperemesis gravidarum on eye healthHealthy pregnant women and pregnant women diagnosed with Hyperemesis gravidarum between 6-14 weeks; eye examination findings were immediately recorded in the system. (within 1 day)

The first-line treatment of Hyperemesis gravidarum (HG) patients ( 6 -14 th weeks of pregnant women ) is fluid depletion and antiemetic therapy, but in severe HG, sepsis, thrombosis secondary to parenteral nutrition, and, albeit rare, Wernicke's encephalopathy (WE). This condition (WE), which is defined as a sign of optic disc swelling that causes a diagnostic dilemma in pregnancy, can be diagnosed with a high index of suspicion by clinical signs and radiological evidence, and generally, patients experience rapid improvement in clinical symptoms with intravenous thiamine therapy. For all this reason, it is extremely important to take necessary precautions for obstetricians. Our primary outcome is to compare the macular thickness and corneal thickness of HG patients participating in the study with normal healthy pregnant women using Optic coherancetomography.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Batman education adn research hospital

🇹🇷

Batman, Turkey

© Copyright 2025. All Rights Reserved by MedPath